Name Address/P.O. Box Postal Code/City Country Additional office Contact Person Telephone Fax Email Website Social Media Number of Employees Founded (year) Areas of Activity External Collaborations
Affimed
Affimed – engaging innate immune cells to fight cancer Affimed (Nasdaq: AFMD) engineers targeted innate immunotherapies, seeking to cure patients by giving them back their innate ability to fight cancer. We are developing mono- and combination therapies to treat hematologic and solid tumours.
›
Im Neuenheimer Feld 582 68120 Heidelberg Germany New York City, US Dr Angela Sickmann +49-6221-6743672 +49-6221-6743649 a.sickmann@affimed.com www.affimed.com
›
LI
›
› › › › › › › ›
›
150 2000
›
Immuno-Oncology
›
›
| Artiva | GHSG (Deutsche Hodgkin Studiengruppe) | Genentech | Leukemia and Lymphoma Society | MSD (Merck & Co.) | NKGen Biotech | Roche | Roivant | The University of Texas, MD Anderson Cancer Center
Our approach Although the human immune system is normally capable of recognising foreign or aberrant cells, cancer cells have acquired highly effective ways to escape immune surveillance. As a result, immune cells such as NK cells and macrophages, which are part of the innate immune system (the first line of defence) cannot recognise tumour cells as foreign or aberrant and therefore cannot fight them. To overcome these limitations, we develop antibodies that activate innate immune cells and redirect them to the tumour, thereby disabling the tumour’s evasion mechanisms. They establish a bridge between either NK cells or macrophages and cancer cells, triggering an immune response that leads to the destruction of tumour cells.
Our ROCK® platform Leveraging our modular and versatile ROCK® (Redirected Optimised Cell Killing) platform, we generate proprietary, next-generation multi-specific antibodies. Our tetravalent (four binding sites), bispecific (two targets) innate cell engagers (ICE® formats) have the ability to bring NK cells or macrophages into proximity to cancer cells and trigger a signal cascade that leads to the destruction of these cancer cells. A number of clinical and preclinical programmes are in development based on the ROCK® platform and our ICE® molecules have shown a favourable safety profile and promising signs of therapeutic efficacy. Our modular ROCK® platform with its versatile features enables the generation of multi-specific antibodies with appropriate properties for tailored treatment including halflife, tissue distribution, and optimal tumour and immune cell targeting. This allows us to tailor our innate cell engagers to specific indications and patient settings.
